Device Trial Radar · NCT05495698
Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Aug 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Dec 13, 2022
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Franciscus GasthuisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 10, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TRICOLON is an investigator initiated, prospective, interventional, open-label, randomized, real-world, multi-centre, 3-arms study in the Netherlands. The primary objective is to investigate in COPD patients if single-inhaler triple therapy (SITT) is superior to multi-inhaler triple therapy (MITT) in terms of adherence to inhaled corticosteroids (ICS) therapy and to investigate if SITT with e-health support is superior to MITT and SITT without e-health support.
Conditions
- Copd
- Adherence, Medication
Interventions
single-inhaler triple therapy (Trimbow)Drug
Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
E-health application: Curavista app & FindAir e-deviceDevice
Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir
multi-inhaler triple therapy (Qvar + Bevespi)Drug
Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adherence to ICS therapyTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Franciscus Gasthuis & Vlietland
Rotterdam, South Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.